LT3057964T - Selektyviai pakeistieji chinolino junginiai - Google Patents

Selektyviai pakeistieji chinolino junginiai

Info

Publication number
LT3057964T
LT3057964T LTEP14790937.8T LT14790937T LT3057964T LT 3057964 T LT3057964 T LT 3057964T LT 14790937 T LT14790937 T LT 14790937T LT 3057964 T LT3057964 T LT 3057964T
Authority
LT
Lithuania
Prior art keywords
selectively substituted
substituted quinoline
quinoline compounds
compounds
selectively
Prior art date
Application number
LTEP14790937.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Lynn Hawkins
Eric Carlson
Hans Hansen
Matthew MACKEY
Shawn Schiller
Chikako OGAWA
Heather Davis
Atsushi Endo
Sally Ishizaka
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of LT3057964T publication Critical patent/LT3057964T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
LTEP14790937.8T 2013-10-14 2014-10-14 Selektyviai pakeistieji chinolino junginiai LT3057964T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890718P 2013-10-14 2013-10-14
PCT/US2014/060418 WO2015057659A1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds

Publications (1)

Publication Number Publication Date
LT3057964T true LT3057964T (lt) 2020-02-25

Family

ID=51842881

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14790937.8T LT3057964T (lt) 2013-10-14 2014-10-14 Selektyviai pakeistieji chinolino junginiai

Country Status (35)

Country Link
US (5) US9428495B2 (enExample)
EP (3) EP3057964B1 (enExample)
JP (3) JP6223563B2 (enExample)
KR (2) KR102103256B1 (enExample)
CN (2) CN110105346B (enExample)
AR (1) AR098014A1 (enExample)
AU (2) AU2014334554B2 (enExample)
BR (1) BR112016008359B1 (enExample)
CA (1) CA2927510C (enExample)
CL (1) CL2016000662A1 (enExample)
CY (1) CY1122776T1 (enExample)
DK (1) DK3057964T3 (enExample)
ES (1) ES2773303T3 (enExample)
HR (1) HRP20200147T1 (enExample)
HU (1) HUE048706T2 (enExample)
IL (2) IL245131B (enExample)
JO (1) JO3554B1 (enExample)
LT (1) LT3057964T (enExample)
MA (1) MA39034B1 (enExample)
MD (1) MD4635C1 (enExample)
MX (2) MX364657B (enExample)
MY (1) MY192489A (enExample)
PE (1) PE20160608A1 (enExample)
PH (1) PH12016500642B1 (enExample)
PL (1) PL3057964T3 (enExample)
PT (1) PT3057964T (enExample)
RS (1) RS59911B1 (enExample)
RU (1) RU2679622C2 (enExample)
SG (3) SG11201602818TA (enExample)
SI (1) SI3057964T1 (enExample)
SM (1) SMT202000076T1 (enExample)
TW (2) TWI702218B (enExample)
UA (1) UA120039C2 (enExample)
WO (1) WO2015057659A1 (enExample)
ZA (4) ZA201601882B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2794571T1 (sl) * 2011-12-22 2017-03-31 Merck Patent Gmbh Novi heterociklični karboksamidi kot modulatorji aktivnosti kinaze
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
PE20160608A1 (es) 2013-10-14 2016-07-08 Eisai Randd Man Co Ltd Compuestos de quinolina selectivamente sustituida
EP3889146A1 (en) * 2015-12-17 2021-10-06 Merck Patent GmbH Polyheterocyclic tlr7/8 antagonists and their uses for treating immune disorders
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
KR102635885B1 (ko) * 2016-08-08 2024-02-14 메르크 파텐트 게엠베하 Tlr7/8 안타고니스트 및 이의 용도
CR20190119A (es) * 2016-09-09 2019-06-03 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
WO2018049089A1 (en) * 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
US10793553B2 (en) * 2017-07-18 2020-10-06 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
CN111542515B (zh) * 2017-10-30 2023-12-05 科罗拉多州立大学董事会法人团体 Toll样受体8(tlr8)特异性拮抗剂及其制备方法和用途
KR102849449B1 (ko) 2017-11-14 2025-08-21 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
CA3085333A1 (en) 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
TWI689510B (zh) 2017-12-18 2020-04-01 美商必治妥美雅史谷比公司 4-氮雜吲哚化合物
ES2977657T3 (es) 2017-12-19 2024-08-28 Bristol Myers Squibb Co Compuestos de 6-azaindol
CA3086172A1 (en) * 2017-12-19 2019-06-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
JP7313354B2 (ja) 2017-12-19 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
MX2020005513A (es) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
CN111491918B (zh) 2017-12-20 2023-10-24 百时美施贵宝公司 芳基和杂芳基取代的吲哚化合物
CN108101860B (zh) * 2018-02-08 2021-11-23 苏州敬业医药化工有限公司 顺式-2，6-二甲基吗啉的制备方法
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
US12157746B2 (en) 2018-06-05 2024-12-03 Hoffmann-La Roche Inc. Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EP3805203A4 (en) * 2018-06-07 2022-02-23 Daiichi Sankyo Company, Limited AZETIDE DERIVATIVE AND PRODRUG THEREOF
JP7434186B2 (ja) * 2018-06-12 2024-02-20 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
US11098027B2 (en) * 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
EP3826724B1 (en) 2018-07-23 2022-10-05 F. Hoffmann-La Roche AG Novel piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
US12252484B2 (en) 2018-09-06 2025-03-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
EP3847165A1 (en) * 2018-09-07 2021-07-14 F. Hoffmann-La Roche AG Novel pyrrolidine amine compounds for the treatment of autoimmune disease
JP2022502480A (ja) * 2018-09-11 2022-01-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのピラゾロピリジンアミン化合物
EP3623369B1 (en) 2018-09-12 2023-10-25 F. Hoffmann-La Roche AG Novel morpholinyl amine compounds for the treatment of autoimmune disease
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP7597709B2 (ja) 2018-10-24 2024-12-10 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
TW202031650A (zh) * 2018-11-09 2020-09-01 瑞士商赫孚孟拉羅股份公司 用於治療自體免疫疾病之吡唑化合物
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN114126713B (zh) 2019-05-09 2023-12-08 百时美施贵宝公司 经取代的苯并咪唑酮化合物
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021048200A1 (en) 2019-09-10 2021-03-18 F. Hoffmann-La Roche Ag Novel quinoline compounds for the treatment of autoimmune disease
CN113329999B (zh) * 2019-09-23 2022-07-01 冰洲石生物科技公司 具有雄激素受体降解活性的新型取代的喹啉-8-甲腈衍生物及其用途
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
US12448395B2 (en) 2019-10-01 2025-10-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
CN114599652B (zh) 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
CN114728976B (zh) * 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
JP2023502238A (ja) * 2019-11-19 2023-01-23 エフ．ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのトリアザトリサイクル化合物
EP4061821B1 (en) * 2019-11-20 2025-08-06 F. Hoffmann-La Roche AG Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
CN114761406B (zh) * 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
WO2021112251A1 (ja) * 2019-12-06 2021-06-10 第一三共株式会社 アゼチジンスルホンアミド化合物
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2022143985A1 (zh) * 2020-12-31 2022-07-07 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
CA3220429A1 (en) * 2021-06-11 2022-12-15 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
IL62783A (en) 1981-05-04 1987-01-30 Usv Pharma Corp Antihypertensive 1,4-thiazine,1,4-thiazepine and 1,4-thiazocine compounds,method for the preparation thereof and pharmaceutical compositions containing the same
JPS5890511A (ja) 1981-11-25 1983-05-30 Otsuka Pharmaceut Co Ltd 抗菌剤
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JPH08295690A (ja) 1995-04-26 1996-11-12 Tokuyama Corp クロメン化合物
JP2000510865A (ja) * 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンカルボキサミド
JP4382880B2 (ja) 1996-10-11 2009-12-16 興和株式会社 新規なジアミド化合物及びこれを含有する医薬
DE19643048A1 (de) 1996-10-18 1998-04-23 Daimler Benz Ag Verbindungen und deren Verwendung sowie Verfahren zur Herstellung von flüssigkristallinen Polymeren daraus
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
KR100709498B1 (ko) 1999-04-28 2007-04-20 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 디아릴 산 유도체
DE19936437A1 (de) 1999-08-03 2001-02-08 Aventis Cropscience Gmbh Kombinationen aus Herbiziden und Safenern
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
CZ20023033A3 (cs) 2000-03-17 2003-01-15 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselin jako inhibitory matrixových metaloproteáz a TNF-alfa
NZ521245A (en) 2000-03-17 2004-04-30 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
WO2002018335A1 (en) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Cyclic amine derivatives
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1371376A4 (en) 2001-03-19 2009-03-25 Nippon Shinyaku Co Ltd Antipruritic agents
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
DE10222166A1 (de) 2002-05-20 2003-12-11 Fraunhofer Ges Forschung Chirale Verbindungen und deren Verwendung
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7041693B2 (en) 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
AU2003284001A1 (en) 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
GB2396154B (en) 2002-10-15 2007-02-28 Merck Patent Gmbh 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices
EP1594842A1 (en) 2003-02-22 2005-11-16 MERCK PATENT GmbH Cyanopyridone derivatives as liquid crystals
CA2517291C (en) 2003-03-19 2012-05-08 Exelixis, Inc. Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use
CA2523125A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
JP2006526669A (ja) 2003-04-01 2006-11-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 重合可能なキラル化合物
CN1809357B (zh) * 2003-06-20 2010-12-22 科勒制药有限公司 小分子Toll样受体(TLR)拮抗剂
AU2004257149A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
US7211671B2 (en) 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
JP2005132834A (ja) * 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
CN1291977C (zh) * 2003-10-20 2006-12-27 复旦大学 多取代喹啉衍生物功能材料及其制备方法和应用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA012621B1 (ru) 2003-11-07 2009-10-30 Чирон Корпорейшн Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
TWI316955B (en) 2003-11-19 2009-11-11 Chisso Corp Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof
NZ548181A (en) 2004-02-04 2010-03-26 Neurosearch As Diazabicyclo[3.2.2]nonane derivatives as cholinergic receptor modulators and nicotinic acetylcholine receptor ligands
US20070185178A1 (en) 2004-02-18 2007-08-09 Aatrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
US20070004679A1 (en) 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
MXPA06013329A (es) 2004-05-17 2007-02-22 Acadia Pharm Inc Moduladores del receptor androgeno, y metodo para tratar enfermedades en el que se utilizan los mismos.
EP1751150A2 (en) 2004-05-19 2007-02-14 Neurosearch A/S Novel azabicyclic aryl derivatives
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006068594A1 (en) 2004-12-21 2006-06-29 Astrazeneca Ab HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006110276A2 (en) 2005-04-08 2006-10-19 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
MX2007015853A (es) 2005-06-30 2008-02-22 Bionumerik Pharmaceuticals Inc Analogos de platino con ligandos de monoimina.
JP2007045752A (ja) 2005-08-10 2007-02-22 Takeda Chem Ind Ltd ５員芳香族複素環誘導体、その製造法および用途
JP2007131765A (ja) 2005-11-11 2007-05-31 Fujifilm Corp 液晶性組成物
KR20080080395A (ko) 2005-12-21 2008-09-03 아보트 러보러터리즈 항바이러스 화합물
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
US7989458B2 (en) 2006-07-14 2011-08-02 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
AR065806A1 (es) * 2007-03-22 2009-07-01 Astrazeneca Ab Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
EP2170059B1 (en) 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
US8445480B2 (en) 2007-06-20 2013-05-21 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
JP5057056B2 (ja) 2007-08-03 2012-10-24 Ｊｓｒ株式会社 液晶配向剤、液晶配向膜の製造方法、ポリアミック酸およびポリイミドならびにジアミン化合物
JP2009108152A (ja) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd 重合性化合物および光学フィルム
CN101910164A (zh) 2007-10-29 2010-12-08 先灵公司 作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物
CN101440062B (zh) 2007-11-23 2011-09-28 齐齐哈尔大学 N-酰基-8-氨基喹啉衍生物的合成及其作为荧光分子探针的应用
JP2009149754A (ja) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd 重合性化合物および該重合性化合物を重合してなる光学フィルム
JP2011514898A (ja) 2008-03-07 2011-05-12 エフ．ホフマン−ラ ロシュ アーゲー ２−アミノキノリン誘導体
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009137081A2 (en) 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
WO2009139438A1 (ja) 2008-05-15 2009-11-19 田辺三菱製薬株式会社 光学活性カルボン酸の製造方法
CA2726158A1 (en) 2008-06-11 2009-12-17 Dana Farber Cancer Institute Compounds and compositions useful for the treatment of malaria
CA2727245A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of faah
CA2727242A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of faah
PT3289876T (pt) 2008-06-16 2022-10-28 Univ Tennessee Res Found Compostos para o tratamento do câncer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
US8673941B2 (en) 2008-08-04 2014-03-18 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of FAAH
WO2010018874A1 (en) 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
JP2010066630A (ja) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd 光学フィルムの製造方法及び光学フィルム
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010046445A2 (en) 2008-10-23 2010-04-29 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
EP2373634B1 (en) 2008-12-05 2015-11-11 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
CN101759683B (zh) 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
EP2398771B1 (en) 2009-02-18 2015-07-29 Boehringer Ingelheim International GmbH Heterocyclic compounds which modulate the cb2 receptor
CN101838264B (zh) 2009-03-16 2014-12-03 住友化学株式会社 化合物、光学膜和光学膜的制造方法
JP5899607B2 (ja) 2009-03-16 2016-04-06 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
JP2011006360A (ja) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
WO2011017142A1 (en) 2009-08-06 2011-02-10 Merck Patent Gmbh Novel bicyclic urea compounds
JP2011042606A (ja) 2009-08-20 2011-03-03 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
WO2011025565A1 (en) 2009-08-31 2011-03-03 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
KR20120063515A (ko) 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Ｐｉ３ 키나제 억제제 및 이들의 용도
EA020586B1 (ru) 2009-09-10 2014-12-30 Новартис Аг СУЛЬФОНАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ СЕМЕЙСТВА Bcl-2, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ РАКА
CN102686551B (zh) 2009-12-01 2014-11-12 住友化学株式会社 环烷二羧酸单酯的制造方法
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
WO2011088192A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
US8901156B2 (en) 2010-01-13 2014-12-02 Tempero Pharmaceuticals, Inc. Compounds and methods
KR20120123691A (ko) 2010-01-28 2012-11-09 머크 샤프 앤드 돔 코포레이션 통증 및 기타의 적응증의 치료를 위한 제약 조성물
AU2011215638B2 (en) 2010-02-11 2016-04-28 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
KR20120130777A (ko) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
CA2794724A1 (en) 2010-04-22 2011-10-27 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
WO2011133729A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
AU2011242688B2 (en) 2010-04-23 2015-01-22 Kineta, Inc. Anti-viral compounds
US20120142701A1 (en) 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
JP5652011B2 (ja) 2010-06-10 2015-01-14 住友化学株式会社 光学フィルム
EP2593107A1 (en) 2010-07-12 2013-05-22 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2609092B1 (en) 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US9006187B2 (en) 2010-09-10 2015-04-14 Green Cross Corporation Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
KR20140015279A (ko) 2010-12-23 2014-02-06 솔베이(소시에떼아노님) 트리스 동종리간드 금속 착물을 위한 fac-이성질체의 제조
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
CA2829803A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
CN102675289B (zh) 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
TW201311149A (zh) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
CA2840883C (en) 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
EP2758375A1 (en) 2011-09-23 2014-07-30 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
PE20160608A1 (es) 2013-10-14 2016-07-08 Eisai Randd Man Co Ltd Compuestos de quinolina selectivamente sustituida

Also Published As

Publication number Publication date
JP6639607B2 (ja) 2020-02-05
IL245131A0 (en) 2016-06-30
CN106414432A (zh) 2017-02-15
EP3057964B1 (en) 2019-12-04
RU2679622C2 (ru) 2019-02-12
MA39034B1 (fr) 2018-09-28
MX364657B (es) 2019-05-03
SG11201602818TA (en) 2016-05-30
CA2927510A1 (en) 2015-04-23
KR102103256B1 (ko) 2020-04-23
SI3057964T1 (sl) 2020-03-31
TW201838988A (zh) 2018-11-01
CY1122776T1 (el) 2021-05-05
MA39034A1 (fr) 2018-01-31
KR20160068949A (ko) 2016-06-15
IL245131B (en) 2018-11-29
US10087174B2 (en) 2018-10-02
PE20160608A1 (es) 2016-07-08
AU2018264036B2 (en) 2020-07-16
US20180354939A1 (en) 2018-12-13
CL2016000662A1 (es) 2016-12-16
TWI702218B (zh) 2020-08-21
PL3057964T3 (pl) 2020-05-18
MX374600B (es) 2025-03-06
ZA201601882B (en) 2019-09-25
MX2019005192A (es) 2019-10-21
SG10201704327RA (en) 2017-06-29
JP6223563B2 (ja) 2017-11-01
ZA201608132B (en) 2019-01-30
KR20180011874A (ko) 2018-02-02
CN110105346B (zh) 2023-03-10
EP3057964A1 (en) 2016-08-24
RU2016118619A (ru) 2017-11-22
TW201602100A (zh) 2016-01-16
US20160326161A1 (en) 2016-11-10
JP6420878B2 (ja) 2018-11-07
MY192489A (en) 2022-08-23
ZA201801112B (en) 2020-10-28
HK1223092A1 (en) 2017-07-21
MX2016004632A (es) 2016-10-26
ES2773303T3 (es) 2020-07-10
JO3554B1 (ar) 2020-07-05
MD4635B1 (ro) 2019-06-30
USRE47193E1 (en) 2019-01-08
KR101823488B1 (ko) 2018-01-30
BR112016008359B1 (pt) 2022-07-19
JP2017226700A (ja) 2017-12-28
BR112016008359A2 (enExample) 2017-10-03
IL262970A (en) 2018-12-31
EP3995495A1 (en) 2022-05-11
TWI624467B (zh) 2018-05-21
US20150105370A1 (en) 2015-04-16
AU2014334554A1 (en) 2016-06-02
AU2018264036A1 (en) 2018-12-06
PH12016500642A1 (en) 2016-05-30
MD20160052A2 (ro) 2016-09-30
CN106414432B (zh) 2019-06-14
AR098014A1 (es) 2016-04-27
JP2016535003A (ja) 2016-11-10
IL262970B (en) 2019-10-31
PT3057964T (pt) 2020-02-25
MD4635C1 (ro) 2020-01-31
WO2015057659A1 (en) 2015-04-23
HUE048706T2 (hu) 2020-08-28
JP2019023220A (ja) 2019-02-14
CA2927510C (en) 2022-03-01
RU2016118619A3 (enExample) 2018-05-23
US9428495B2 (en) 2016-08-30
SG10202103278TA (en) 2021-04-29
PH12016500642B1 (en) 2016-05-30
UA120039C2 (uk) 2019-09-25
SMT202000076T1 (it) 2020-03-13
US20180030045A1 (en) 2018-02-01
NZ720129A (en) 2021-03-26
RS59911B1 (sr) 2020-03-31
AU2014334554B2 (en) 2018-12-06
DK3057964T3 (da) 2020-02-24
EP3626717A1 (en) 2020-03-25
HRP20200147T1 (hr) 2020-05-01
ZA201905393B (en) 2020-11-25
CN110105346A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
ZA201905393B (en) Selectively substituted quinoline compounds
IL267031B (en) Selectively converted quinoline compounds
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201310542D0 (en) Compounds
GB201302927D0 (en) Compounds
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
GB201311953D0 (en) Compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201312901D0 (en) Compounds
EP2948457A4 (en) COMPOUNDS
GB201316014D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201318323D0 (en) Compounds
GB201317118D0 (en) Compounds
GB201316717D0 (en) Compounds
GB201315947D0 (en) Compounds
GB201315253D0 (en) Compounds
GB201314700D0 (en) Compounds
GB201314681D0 (en) Compounds
GB201311943D0 (en) Compounds
GB201310464D0 (en) Compounds
GB201310115D0 (en) Compounds
GB201310047D0 (en) Compounds
GB201309728D0 (en) Compounds